---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-083799"
form_type: "8-K"
ticker: "CRSP"
cik: "0001674416"
company_name: "CRISPR Therapeutics AG"
filed_at: "2025-06-09T23:59:59+00:00"
generated_at: "2026-05-19T17:16:29.121447+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.4
calibrated_materiality_score: 0.4
confidence: "high"
source: SEC EDGAR
---

# CRISPR Therapeutics shareholders elect new director, approve board size increase at 2025 AGM

## Summary
- New director Briggs W. Morrison, M.D. elected; board size maximum increased.
- Binding votes on executive compensation approved with significant against votes (e.g., equity grant for execs: 31.8M for, 9.0M against).
- Non-binding advisory vote on named executive officer compensation passed with 29.1M for vs 11.7M against.
- Shareholders approved amendments to articles of association, effective June 6, 2025, subject to Swiss registration.
- All director nominees re-elected; auditors Ernst & Young re-elected for FY2025.

## SEC filing metadata
- accession: 0000950170-25-083799
- form_type: 8-K
- ticker: CRSP
- cik: 0001674416
- company_name: CRISPR Therapeutics AG
- filed_at: 2025-06-09T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.4
- calibrated_materiality_score: 0.4
- confidence: high
- sec_items: 5.03, 5.07, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1674416/000095017025083799/0000950170-25-083799-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1674416/000095017025083799/crsp-20250605.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-083799
- JSON: https://secwatch.observer/filing/0000950170-25-083799.json
- Plain text: https://secwatch.observer/filing/0000950170-25-083799.txt

## Key facts
- Governance Changes
  CRISPR Therapeutics AG: Shareholders approved amendments to the Articles of Association, as described in the Proxy Statement, effective upon registration in the Commercial Register in Zug, Switzerland on or about June 6, 2025 (effective 2025-06-06).
  - Change: charter amendment
  - Effective: 2025-06-06
  source text: On June 5, 2025, at the 2025 Annual General Meeting of Shareholders (the “Annual Meeting”), the shareholders of CRISPR Therapeutics AG (the “Company”) approved amendments to the articles of association of the Company (the “Articles of Association”) as described in the Company’s proxy statement for the Annual Meeting filed with the Securities and Exchange Commission on April 16, 2025 (the “Proxy Statement”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1674416/000095017025083799/0000950170-25-083799-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.